Anavex Life Sciences Corp. (AVXL)
Anavex Life Sciences is a New York biopharmaceutical company developing drug candidates for Alzheimer's and other brain diseases. It last closed at $0.74 on Nov 17, down 9.49% on the day. AVXL reports earnings on Tue, Nov 24, 2026.
Key Stats
Last 12 monthsNot reported for this period.
From AVXL's SEC filings, latest 10-Q for the period ending Jun 30, 2026 (filed Aug 28). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Technical Analysis
The stock is 57% below its 20 day and 126% below its 50 day average. It is 286% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 20), oversold. The nearest support is the 52 week low at $0.71, and the nearest resistance the Pivot at $0.76.
| RSI (14) | 20.33 | Oversold below 30 | Oversold |
| MACD | -0.22 | Below its signal line | Bearish |
| Stochastic | 4.3 | Near the bottom of its range | Oversold |
| ADX (14) | 55.5 | Strong downtrend | |
| Williams %R | -94.7 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -215.7 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −38.3% | Change over 10 sessions | Bearish |
| ATR (14) | $0.11 | Typical daily range, 14.8% of price |
| RSI (14) | 23.38 | Oversold below 30 | Oversold |
| MACD | -0.67 | Below its signal line | Bearish |
| Stochastic | 1.6 | Near the bottom of its range | Oversold |
| ADX (14) | 24.6 | Weak trend | |
| Williams %R | -98.9 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -131.6 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −71.8% | Change over 10 sessions | Bearish |
| ATR (14) | $0.39 | Typical daily range, 53.0% of price |
What happened before
See how AVXL did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How AVXL has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.
Whale Options Flow
90DNo whale options trades in AVXL in the last 90 days.
AVXL Institutional Ownership
Full report →- ▼56 buying vs 96 selling
- ▲Held by funds +2.6 pts
- ▼Funds holding -16
- ●Superinvestors: 2 added, 2 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 165 | 181 | −8.8% |
| In funds' top 10 | 0 | 0 | – |
| Held by funds | 42.6% | 40.0% | +2.6 pts |
| New / increased | 14 / 42 | 23 / 65 | −36.4% |
| Reduced / sold out | 70 / 26 | 54 / 32 | +11.6% |
| Put/call ratio | 0.02 | 0.00 | +1983.8% |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether AVXL is in one of them and how their past AVXL trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered AVXL in an article yet. Here's the latest on the wider market.
AVXL Congress Trades
All congress trades →| Person | Type | Amount | Traded | Filed | Delay |
|---|---|---|---|---|---|
| Christopher JacobsR · NY | Sell | $1K – $15K | Dec 12, 2022 | Jan 20, 2023 | 39 d |
| Christopher JacobsR · NY | Buy | $1K – $15K | Oct 12, 2022 | Nov 16, 2022 | 35 d |
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About Anavex Life Sciences
Anavex Life Sciences is a clinical stage biopharmaceutical company based in New York. It develops drug candidates for diseases of the central nervous system, including Alzheimer's disease, Parkinson's disease, schizophrenia, Rett syndrome and other rare brain disorders. Its main candidate, blarcamesine, is being studied as an oral treatment that acts on the sigma receptor. The company's intended customers are patients with these conditions and the healthcare providers who treat them.
- Headquarters
- New York, NY




